Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.46 |
| ▸ | PREP | P48147 | 3/20 | 0.46 |
| ▸ | FAP | Q12884 | 3/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 3/20 | 0.41 |
| ▸ | F2 | P00734 | 4/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8564777 | 1.00 | DPP4 (0.46) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL29985759 | 0.97 | PREP (0.44) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL29349875 | 0.96 | DPP4 (0.43) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL29595774 | 0.94 | CHRM3 (0.43) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL29935652 | 0.92 | CHRM3 (0.42) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL29380104 | 0.88 | ACE (0.49) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL29874508 | 0.88 | ACE (0.49) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL1046072 | 0.88 | DPP4 (0.46) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL1046070 | 0.88 | DPP4 (0.46) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL1402279 | 0.88 | CHRM2 (0.42) | DPP4PREPFAPDPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024178352-A2 | BMP SYNTHASE ACTIVATORS AND INHIBITORS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-08-29 | — | — | WO | claimed |
| US-20230374112-A1 | Bioactive Collagen Peptides, Method Of Production Thereof, And Use Thereof | BDC CAPITAL INC. (CA) | 2023-11-23 | — | — | US | claimed |
| WO-2022067445-A1 | BIOACTIVE COLLAGEN PEPTIDES, METHOD OF PRODUCTION THEREOF, AND USE THEREOF | CORPORATION GENACOL CANADA INC. (CA) | 2022-04-07 | — | — | WO | claimed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | BARINTHUS BIOTHERAPEUTICS NORTH AMERICA INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250382360-A1 | Anti-VEGF Single Chain Variable Fusion Protein (RNAT82) | MAGOOLA MATTHIAS (UG) | 2025-12-18 | — | — | US | disclosed |
| US-20250381288-A1 | Anti-VEGF Single Chain Variable Fusion Protein (RNAT92) | NIAZI SARFARAZ K (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250381287-A1 | Anti-VEGF Fusion Protein (RNAT53) | NIAZI SARFARAZ K (US) | 2025-12-18 | — | — | US | disclosed |
| EP-4608437-A2 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | Barinthus Biotherapeutics North America, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4608455-A1 | SELF-ASSEMBLING NANOPARTICLES | Barinthus Biotherapeutics North America, Inc. (US) | 2025-09-03 | — | — | EP | disclosed |
| WO-2022139539-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF SARS-COV-2 INFECTION | 아주대학교산학협력단 | 2022-06-30 | — | — | WO | disclosed |
| US-20220143130-A1 | Peptides Having Immunomodulatory Properties | Riptide Bioscience, Inc. | 2022-05-12 | — | — | US | disclosed |
| EP-3206704-B1 | PEPTIDES HAVING ANTI-INFLAMMATORY PROPERTIES | RIPTIDE BIOSCIENCE INC (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022067445-A1 | BIOACTIVE COLLAGEN PEPTIDES, METHOD OF PRODUCTION THEREOF, AND USE THEREOF | CORPORATION GENACOL CANADA INC. (CA) | 2022-04-07 | — | — | WO | disclosed |
| EP-0545991-B1 | PEPTIDES THAT BLOCK HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS AND METHODS OF USE THEREOF | VAHLNE ANDERS (SE) | 1998-12-02 | — | — | EP | disclosed |
| EP-0545991-B1 | PEPTIDES THAT BLOCK HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS AND METHODS OF USE THEREOF | VAHLNE ANDERS (SE) | 1998-12-02 | — | — | EP | disclosed |
| US-5627035-A | Peptides that block human immunodeficiency virus and methods of use thereof | SYNTELLO VACCINE DEVELOPMENT AB (SE) | 1997-05-06 | — | — | US | disclosed |
| EP-0545991-A1 | PEPTIDES THAT BLOCK HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS AND METHODS OF USE THEREOF | VAHLNE, Anders (SE) | 1993-06-16 | — | — | EP | disclosed |
| WO-1992003147-A1 | PEPTIDES THAT BLOCK HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS AND METHODS OF USE THEREOF | SYNTELLO VACCIN DEVELOPMENT KB (SE) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091097-A1 | COMBINATION TREATMENT REGIMES FOR TREATING CANCER | IL2, IFNG, ICOS | DPP4 2639/4885PREP 914/4885FAP 1715/4885 |
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | DPP4 43/4885PREP 4/4885FAP 165/4885 |
| US-20250381281-A1 | METHODS OF MANUFACTURING PEPTIDE-BASED VACCINES | VIP, HM13, SPPL2B | DPP4 1168/4885PREP 230/4885FAP 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.